Cancer– tag –

This Part focuses on how extrachromosomal DNA (ecDNA) shapes spatial heterogeneity and evolution in glioblastoma (GBM). We outline the extreme copy-number gains of drivers (EGFR/PDGFRA/CDK4) on ecDNA, region-to-region response gaps, and ...

Extrachromosomal DNA (ecDNA) reshapes oncogene dosage, transcription, phenotypes, and spatial organization, thereby accelerating intratumor heterogeneity and therapy resistance. In Part 1, we briefly introduce non-GBM evidence up front a...

For over four decades, KRAS symbolized the “undruggable.” By the mid-2020s, it became the flagship of precision oncology. This final chapter summarizes that evolution—from structural biology to AI-driven therapeutics—and looks ahead to h...

The race to drug KRAS is reshaping not only science but the entire biotech ecosystem. Once deemed “undruggable,” KRAS became a proving ground for startups, academic spinouts, and AI-driven discovery. This part reviews key players—Revolut...

The rise of KRAS inhibitors marked the end of the “undruggable” era—but tumors adapt swiftly. Resistance often stems from a cooperative reactivation between mutant and wild-type RAS. This sixth installment dissects the molecular basis of...

KRAS has evolved from the icon of “undruggable” to the engine of next-generation oncology. Building on the success of allele-selective inhibitors (e.g., G12C), the mid-2020s ushered in three powerful paradigms: RAS(ON) inhibition, pan-KR...

KRAS research has now transcended oncology. Recent studies reveal that KRAS signaling interconnects with immunity, cellular aging, and even regenerative medicine. In this fourth installment, we redefine KRAS as a “life regulator” rather ...

In Part 1, we traced the long struggle to target KRAS and the breakthrough that made the “undruggable” druggable. Now we turn to a crucial question: how do different KRAS alleles shape tumor biology, signaling behavior, and clinical outc...

Few oncogenes have shaped the landscape of cancer research as profoundly as KRAS. Since the first RAS mutation was identified in human bladder cancer cells in 1982, this small GTP-binding protein has fascinated scientists as both a myste...

Takeaway: Lymph-node–targeted amphiphile delivery achieved robust dual CD4/CD8 responses. A data-driven ~9.17× immune threshold aligned with RFS/OS gains and ctDNA negativity in the adjuvant MRD setting. Contents 1. One-Minute Summary 2....

Takeaway: the field is coalescing around shared neoantigens × off-the-shelf × adjuvant MRD. Elicio (ELI-002 7P) leads the pack; academic SLP + poly-ICLC programs and Gritstone’s SLATE-KRAS follow. With V941 halted, the landscape is clear...

Oncology is the tip of the spear for China-origin innovation in global partnering. This article gives you a bird’s-eye view of the major deals, then goes deep into the operating logic behind ADCs, bispecific antibodies, checkpoint inhibi...

In Part 1, we reviewed mechanisms by which NK cells contribute to resistance against immune checkpoint blockade (ICB). In this follow-up article (Part 2), we discuss the clinical implications, potential strategies, and future directions ...

Natural killer (NK) cells have long been recognized as frontline effectors of tumor surveillance. However, recent studies reveal that their role within the tumor microenvironment (TME) is far more complex. NK cells are increasingly impli...

Claudin18.2 (CLDN18.2)-directed ADCs are rapidly emerging as a cornerstone in the treatment of advanced gastric and gastroesophageal junction (GEJ) cancers. Beyond SHR-A1904 and IBI343, several other candidates such as CMG901, EO-3021, a...

In this article, we summarize the phase 1 trial of IBI343, reported in Nature Medicine (July 2025), focusing on its structural innovations, safety, efficacy, and position within the landscape of Claudin18.2-targeted ADCs. Drug Profile: M...

In Part 1 of our feature, we explored Enhertu’s groundbreaking pharmacological profile and its role in launching the second ADC boom. In this concluding part, we shift focus to intellectual property strategies, patent lifespans, and the ...

Antibody–drug conjugates (ADCs) targeting Claudin18.2 (CLDN18.2) have gained increasing attention as a novel therapeutic approach for advanced gastric and gastroesophageal junction (GEJ) cancers. Here, we summarize the phase 1 trial resu...

Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergone a dramatic transformation with the arrival of Daiichi Sankyo and AstraZeneca’s Enhertu, sparki...

This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli...